Efficacy of umbilical cord Mesenchymal Stem Cells on patients with neuromuscular disorders

Phase 3

Recruiting

• Conditions: Condition 1: Dystrophinopathy(Duchenne muscular dystrophy, Becker muscular dystrophy). Condition 2: Spinal muscular atrophy. Condition 3: other Myopathy (Congenital myopathy, Congenital myasthenic syndrome). Condition 4: Charcot-Marie-Tooth).; Muscular dystrophy; Spinal muscular atrophy and related syndromes; Congenital myopathies; Hereditary motor and sensory neuropathy; G71.0; G71.2; G60.0

• Registration Number: IRCT20200426047213N1
• Lead Sponsor: Tehran Islamic Azad university of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 15 June 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

Genetic confirmed patients with Dystrophinopathy(Duchenne muscular dystrophy, Becker muscular dystrophy)
Genetic confirmed patients with Neuropathy(Spinal muscular atrophy, Charcot-Marie-Tooth)
Genetic confirmed patients with other Muscular dystrophy(Limb girdle muscular dystrophy, Congenital muscular dystrophy)
Genetic confirmed patients with other Myopathy (Congenital myopathy, Congenital myasthenic syndrome)

Exclusion Criteria

Patients with cancer
Patients with chromosomal defects
Patients with HIV, HCV, HBV, HTLV1,2
Dissatisfaction for entering the study

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Muscle power. Timepoint: Before study, 6 and 9 and 12 months after Mesenchymal stem cell transplantation. Method of measurement: Walking distance in 6 minutes and muscular force examination.